Patents by Inventor Daad Sayegh
Daad Sayegh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130315896Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: February 11, 2013Publication date: November 28, 2013Inventors: David S.F. Young, Daad Sayegh, Sheung Tat Fan, Ronnie Tung Ping Poon, Terence Kin Wah Lee
-
Patent number: 8388961Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: GrantFiled: September 23, 2011Date of Patent: March 5, 2013Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Daad Sayegh, Sheung Tat Fan, Ronnie Tung Ping Poon, Terence Kin Wah Lee
-
Publication number: 20120020880Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: September 23, 2011Publication date: January 26, 2012Applicant: HOFFMANN-LA ROCHE INC.Inventors: David S. F. Young, Daad Sayegh, Sheung Tat Fan, Ronnie Tung Ping Poon, Terence Kin Wah Lee
-
Patent number: 8048416Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes and to binding assays which utilize the CDMAB of the instant invention.Type: GrantFiled: April 11, 2007Date of Patent: November 1, 2011Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Daad Sayegh, Sheung Tat Fan, Ronnie Tung Ping Poon, Terence Kin Wah Lee
-
Publication number: 20090155262Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: September 18, 2008Publication date: June 18, 2009Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Luis A. G. da Cruz, Daad Sayegh, Kristian Rogers, Shankar Kumar, Paul Hinton
-
Patent number: 7534429Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: GrantFiled: July 26, 2006Date of Patent: May 19, 2009Assignee: Hoffmann-La Roche Inc.Inventors: David S. F. Young, Susan E. Hahn, Helen P. Findlay, Luis A. G. daCruz, Daad Sayegh, Sheung Tat Fan, Ronnie Tung Ping Poon, Terence Kin Wah Lee
-
Publication number: 20090074662Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: November 19, 2008Publication date: March 19, 2009Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Daad Sayegh
-
Patent number: 7485300Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: February 22, 2007Date of Patent: February 3, 2009Assignee: Arius Research Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey, Daad Sayegh
-
Patent number: 7456016Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: GrantFiled: February 22, 2007Date of Patent: November 25, 2008Assignee: Arius Research Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Daad Sayegh
-
Publication number: 20080267864Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: July 1, 2008Publication date: October 30, 2008Inventors: David S.F. Young, Helen P. Findlay, Susan E. Hahn, Lisa M. Cechetto, Fortunata McConkey, Daad Sayegh
-
Patent number: 7442777Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: GrantFiled: February 24, 2006Date of Patent: October 28, 2008Assignee: Arius Research Inc.Inventors: David S. F. Young, Helen P. Findlay, Susan E. Hahn, Luis A. G. da Cruz, Daad Sayegh, Kristian Rogers, Shankar Kumar, Paul Hinton
-
Publication number: 20080044408Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: March 22, 2006Publication date: February 21, 2008Inventors: David Young, Helen Findlay, Susan Hahn, Luis da Cruz, Daad Sayegh, Kristian Rogers
-
Publication number: 20070248538Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: April 11, 2007Publication date: October 25, 2007Inventors: David Young, Daad Sayegh, Sheung Fan, Ronnie Poon, Terence Lee
-
Publication number: 20070202041Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: February 22, 2007Publication date: August 30, 2007Inventors: David Young, Helen Findlay, Susan Hahn, Daad Sayegh
-
Publication number: 20070202042Abstract: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells.Type: ApplicationFiled: February 22, 2007Publication date: August 30, 2007Inventors: David Young, Helen Findlay, Susan Hahn, Lisa Cechetto, Fortunata McConkey, Daad Sayegh
-
Publication number: 20070189964Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: March 9, 2007Publication date: August 16, 2007Inventors: David Young, Daad Sayegh, Sheung Fan, Ronnie Poon, Terence Lee
-
Publication number: 20070025912Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: February 24, 2006Publication date: February 1, 2007Inventors: David Young, Helen Findlay, Susan Hahn, Luis da Cruz, Daad Sayegh, Kristian Rogers, Shankar Kumar, Paul Hinton
-
Publication number: 20060269481Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of primary and metastatic human tumor cells; and most particularly to the use of an isolated monoclonal antibody or cancerous disease modifying antibodies (CDMAB) thereof, optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response in such human tumors, e.g. any primary or metastatic tumor sites which arise from hepatocytes. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: July 26, 2006Publication date: November 30, 2006Inventors: David Young, Susan Hahn, Helen Findlay, Luis daCruz, Daad Sayegh, Sheung Fan, Ronnie Poon, Terence Lee
-
Publication number: 20060210474Abstract: This invention relates to the diagnosis and treatment of cancerous diseases, particularly to the mediation of cytotoxicity of tumor cells; and most particularly to the use of cancerous disease modifying antibodies (CDMAB), optionally in combination with one or more chemotherapeutic agents, as a means for initiating the cytotoxic response. The invention further relates to binding assays which utilize the CDMAB of the instant invention.Type: ApplicationFiled: March 3, 2006Publication date: September 21, 2006Inventors: David Young, Helen Findlay, Susan Hahn, Luis da Cruz, Daad Sayegh, Kristian Rogers